Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Thursday, BidAskClub reports.
SYRS has been the topic of several other research reports. Piper Sandler lifted their price target on shares of Syros Pharmaceuticals from $14.00 to $18.00 in a research report on Friday, August 7th. Roth Capital lifted their price target on shares of Syros Pharmaceuticals from $17.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, October 26th. JMP Securities lifted their price target on shares of Syros Pharmaceuticals from $16.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. HC Wainwright raised shares of Syros Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $11.00 to $15.00 in a research report on Wednesday. Finally, Alliance Global Partners assumed coverage on shares of Syros Pharmaceuticals in a research report on Tuesday, September 22nd. They set a “buy” rating and a $18.00 price target on the stock. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $15.38.
SYRS opened at $8.26 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.85 and a quick ratio of 4.85. The company’s 50 day simple moving average is $8.60 and its two-hundred day simple moving average is $10.03. Syros Pharmaceuticals has a 1-year low of $4.26 and a 1-year high of $14.69. The firm has a market capitalization of $377.99 million, a price-to-earnings ratio of -4.86 and a beta of 1.85.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, August 6th. The company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.02. The business had revenue of $3.19 million for the quarter, compared to analyst estimates of $2.19 million. Syros Pharmaceuticals had a negative net margin of 1,114.79% and a negative return on equity of 94.59%. On average, equities analysts anticipate that Syros Pharmaceuticals will post -1.52 earnings per share for the current fiscal year.
In related news, Director Richard A. Young sold 5,673 shares of Syros Pharmaceuticals stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $8.75, for a total value of $49,638.75. Following the completion of the sale, the director now owns 335,201 shares in the company, valued at approximately $2,933,008.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard A. Young sold 5,990 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $12.59, for a total transaction of $75,414.10. Following the completion of the transaction, the director now owns 347,181 shares of the company’s stock, valued at approximately $4,371,008.79. The disclosure for this sale can be found here. Insiders sold a total of 22,933 shares of company stock valued at $254,582 in the last quarter. 14.80% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of SYRS. ARK Investment Management LLC grew its stake in shares of Syros Pharmaceuticals by 31.7% in the third quarter. ARK Investment Management LLC now owns 11,212,506 shares of the company’s stock worth $99,119,000 after acquiring an additional 2,699,373 shares in the last quarter. FMR LLC grew its stake in shares of Syros Pharmaceuticals by 5.5% in the second quarter. FMR LLC now owns 6,623,200 shares of the company’s stock worth $70,603,000 after acquiring an additional 344,216 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Syros Pharmaceuticals by 5.7% in the second quarter. Vanguard Group Inc. now owns 1,901,373 shares of the company’s stock worth $20,269,000 after acquiring an additional 103,005 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of Syros Pharmaceuticals by 126.7% in the second quarter. Two Sigma Advisers LP now owns 182,300 shares of the company’s stock worth $1,943,000 after acquiring an additional 101,900 shares in the last quarter. Finally, Invesco Ltd. acquired a new position in shares of Syros Pharmaceuticals in the first quarter worth $534,000. Institutional investors and hedge funds own 97.66% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company’s lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Featured Article: Analyst Ratings
Receive News & Ratings for Syros Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Syros Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.